|
|
|
연간정보 서비스
The Outlook for Pharmaceuticals in Western Europe
|
Abstract
Description
Market growth in the mature markets of Western Europe is assured over the coming years by the health needs of ageing populations, and will be driven by investment in innovative medicines, particularly in the hospital market. Growth, however, will be tempered somewhat by the effects of the global economic recession in the short term. The leading markets are projected to average a CAGR of 2.1% in US dollar terms up to 2016, to represent a combined pharmaceutical market value of over US$240 billion.
What factors are affecting pharmaceutical market growth?
Demand for pharmaceutical products is set to increase over the coming years, in order to fulfil the health needs of the ageing population. Meanwhile, the trend towards generics is set to continue, with several major patent expiries coming up, and with more governments introducing or expanding generic substitution as a cost-containment measure.
Recent austerity measures, introduced to deal with the impact of the economic recession, have included drug price cuts or discounts in markets such as France, Germany, Greece, Italy and Spain. These price cuts will have an impact across Western Europe, as many other countries use a reference pricing system. These price cuts could limit market growth and there are also fears that lower prices could lead to higher levels of parallel exports.
The hospital market is expected to be the main driver of growth in Western European markets, with increasing investment in expensive, innovative products to treat chronic diseases, such as cancer. The investment from hospitals into new drugs will offset the falling prices of mature drugs that are soon to go off patent. There are opportunities to further explore biotechnology advances and reformulations, which will drive the market forward in the long term.
THESE REPORTS ANALYSE THE ISSUES
The Outlook for Pharmaceutical Markets in Western Europe is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include four completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series.
HIGHLIGHTS FROM THE REGION
FRANCE
France has one of the highest pharmaceutical per capita consumption levels in the world. The French pharmaceutical market is also one of the world's largest. Overall pharmaceutical market growth has been comparatively low in recent years and is expected to average a moderate CAGR in the medium term, with government cost-containment programmes exerting downward pressure on reimbursable products. The hospital market has been much more dynamic with growth rates twice this figure in recent years, although growth rates are now falling due to greater regulatory controls in this sector and fewer innovative drugs coming to market. The underdeveloped generics market is undergoing rapid expansion, boosted by government incentives and the loss of patent protection for several high-volume products. The stagnating OTC market has also started to expand, as a result of government moves to end reimbursement for a wide range of products assigned a low medical value rating.
GERMANY
Germany's economy depends heavily on exports and was therefore hit hard by the global downturn. However, GDP is expected to strengthen over the next five years. The German pharmaceutical market is the largest in Europe. Growth in recent years has tended to be uneven, as government reforms take effect on pricing and/or reimbursement. A new law passed in November 2010, designed to bring down the average price of drugs, is expected to dampen growth slightly over the next few years. The pharmaceutical market is projected to increase at a low CAGR between 2011 and 2016. The law reduces the power that pharmaceutical companies have in deciding what to charge for new prescription drugs. New, innovative drugs have been targeted as they were entirely responsible for the increase in drug spending in 2009. The German biotechnology market is expanding; biopharmaceuticals are expected to represent a fifth of the overall pharmaceutical market by 2020, according to Sandoz.
ITALY
The size of the population and the provision of universal healthcare under the national health service ensures that the Italian pharmaceutical market remains the third largest in Europe despite the market having the lowest growth rate of all the developed economies. The Italian population is ageing and the percentage over 65 years has already exceeded 20% and is set to rise still further with a corresponding increase in chronic and long-term medical conditions. This will inevitably increase demand for pharmaceutical products, placing additional financial strain on the working population to support those of pensionable age. However, cost-containment measures are restricting growth in the Italian pharmaceutical market, particularly in the retail pharmacy market. While growth in the pharmacy market in Italy is slow, demand for pharmaceuticals in hospitals increased by a double-digit CAGR between 2006 and 2009, to account for nearly a quarter of the total pharmaceutical market.
SPAIN
The Spanish pharmaceutical market ranks fifth highest in Western Europe; in per capita terms, it ranks much lower. FARMAINDUSTRIA believes that new pharmaceutical medicines will be entering the market in the coming years, together with biologic medicines. The economic slowdown has affected the pharmaceutical industry. Espicom projects a low CAGR in both euro and US dollar terms between 2011 and 2016; the CAGR in US dollar terms is lower than previously projected due to a weaker projected exchange of the euro against the US dollar. The pharmacy sector is expected to increase at a lower rate than the hospital sector, but cost-containment policies will affect both sectors. Almirall and Esteve are the best positioned local companies. In August 2011, Spain passed a new Royal Decree that included a number of new austerity measures to help reduce the country's budget deficit; some measures affected the health sector.
UNITED KINGDOM
The UK pharmaceutical market is set to experience moderate growth over the coming years, tempered slightly by the effects of the economic recession. Deep public spending cuts are underway, with health expenditure experiencing very limited growth over the next few years. The Health and Social Care Bill, which outlines a set of plans to reform the NHS, was amended in June 2011. The overall principle of the reforms remains the same, with a shift in focus to improving healthcare outcomes rather than meeting targets, and a greater emphasis on quality of care. The Cancer Drugs Fund came into force in April 2011, providing £600.0 million (US$938.9 million) over three years to increase patient access to new cancer drugs. There are plans to introduce value-based pricing in place of the PPRS when it expires in 2013, in order to promote innovation and ensure better access for patients to effective drugs.
Table of Contents
AUSTRIA
- EXECUTIVE SUMMARY SUMMARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Projections
- Outlook
- Imports
- Domestic Production
- Trade Associations
- Domestic Producers
- Ebewe Pharma GmbH
- Genericon Pharma GmbH
- Gerot Pharmazeutika
- Sanochemia Pharmazeutika AG
- Sigmapharm GmbH
- Multinational Manufacturers
- Boehringer Ingelheim Austria GmbH
- Fresenius Kabi Austria GmbH
- Nycomed Austria GmbH
- Octopharma Pharmazeutika Produktions GmbH
- Sandoz GmbH
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic Drugs
- National Procedures
- Advertising
- Intellectual Property
- Supplementary Protection Certificates
- Data exclusivity
- Pricing and Reimbursement
- Pricing
- Reimbursement
- Rational Use of Pharmaceuticals
- Pharmaceutical Distribution
- Distributors
- Chemomedica
- Herba Chemosan Apotheker AG
- Jacoby Pharmazeutika AG
- Kwizda GmbH
- Phoenix Arzneiwarengroshandlung GmbH
- Parallel Imports
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases/ Morbidity
- HIV/ AIDS
- Cancer Incidence
- Healthcare System
- Hospital Care
- Outpatient Care
- Medical Staff
- Financing and Health Insurance
- Healthcare Reform, 2005
- Health Expenditure
- Healthcare Infrastructure
- Inpatient Analysis
- Ambulatory Care
- Healthcare Personnel
- DIRECTORY
- Healthcare Organisations
- Trade Associations
- Distributors
- Domestic Producers and Multinational Manufacturers
List of Tables
- Key Data Projections, 2009-2014
- Summary of the Austrian Pharmaceutical Market, 2009
- Pharmaceutical Market by Type in Retail Prices, 2007
- Pharmaceutical Sales at Wholesale Prices (Euro millions), 2003-2007
- Leading Therapeutic Areas Ranked by Sales, 2006-2008 (% by value)
- Leading Therapeutic Areas Ranked by Sales, 2006-2008 (% by volume)
- Generics Market Share 2000-2007 (%)
- OTC Sales by Product, 2004-2008 (Euro millions)
- Key Market Projections, 2009-2014
- Espicom Analysis of the Austrian Pharmaceutical Market, 2009
- SWOT Analysis of the Austrian Pharmaceutical Market, 2009
- Imports of Pharmaceuticals by Category, 2004-2008 (US$000s)
- Import Trends, 2007-2008 (US$000s)
- Leading Suppliers of Raw Materials, 2008 (US$000s)
- Leading Suppliers of Medicaments, 2008 (US$000s)
- Pharmaceutical Manufacturing & Suppliers, 2007
- Austrian Pharmaceutical Production, 2004-2008 (Euros 000s)
- Exports of Pharmaceuticals, 2004-2008 (US$000s)
- Export Trends, 2007-2008 (US$000s)
- Leading Destinations, 2008 (US$000s)
- Authorised Pharmaceuticals 2001-2007
- Number of Medicinal Products by Classification, 2005-2009
- Pharmacy Outlets, 2001-2007
- Pharmacy Outlets by Region, 2000-2007*
- Summary of Demographic Data, 2007
- Projected Population, 2009-2014
- Registered Causes of Death, 2006-2007
- Healthcare Expenditure, 2009
- Health Expenditure, 2006-2007 (Million Euros)
- Health Insurance System Expenditure, 2004-2007* (Million Euros)
- Projected Health Expenditure, 2009-2014
- Hospitals and Beds by Type, 2002-2007
- Number of Beds by Specialty, 2007
- Hospital Activity Summary, 2004-2007
- Inpatient Discharges by Diagnosis, 2005-2006
- Day Cases in Acute Hospitals by Diagnosis, 2006
- Outpatient Visits by Specialist, 2007
- Number of Physicians, 2006-2007
- Practising Specialists, 2006-2007
- Nursing Personnel by Region, 2007
- Hospital Staff, 2006-2007
- Dentists by Region, 2003-2007
- Projected Total Number of Physicians, 2009-2014
List of Figures
- Radar Graph of the Austrian Pharmaceutical Market, 2009
BELGIUM
- EXECUTIVE SUMMARY SUMMARY
- PHARMACEUTICAL MARKET ANALYSIS
- Size
- Market Structure
- Retail Pharmacy Sector
- Reimbursable Drugs - Retail Pharmacy Market
- Hospital Sector
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Association(s)
- pharma.be
- FeBelGen
- Health, Science and Technology Group
- Local Manufacturers
- Multinational Manufacturers
- GlaxoSmithKline
- Janssen-Cilag / Janssen Pharmaceutica
- Pfizer
- Schering-Plough
- Exports
- Research & Development
- Janssen Research Foundation
- GlaxoSmithKline Biologicals
- UCB Pharma
- PHARMACEUTICAL REGULATORY ANALYSIS
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic drugs
- Federal Drugs Agency / National Procedure
- Advertising
- Pricing & Reimbursement
- Pricing
- Reference Pricing
- Cost Control Policy
- Reimbursement
- Improved Access for Innovative Medicines
- Category A
- Category B
- Category C
- Hospital Drugs
- Kiwi Style System of Reimbursement
- Intellectual Property
- PHARMACEUTICAL DISTRIBUTION
- Wholesaling
- Aprophar/Alpha Repartition
- CERP Phardip
- Febelco
- Laboratoria Flandria
- Pharma Belgium
- Retailing
- HEALTHCARE ANALYSIS
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Non-communicable Diseases
- Cancer
- Cardiovascular disorders
- Diabetes
- Mental disorders
- Neurological disorders
- Respiratory disorders
- Musculoskeletal disorders
- Sexually transmitted infections
- HIV / AIDS
- Healthcare System
- Hospital Services
- Ambulatory Services
- Health Insurance
- Health Expenditure
- Healthcare Infrastructure
- Inpatient Analysis
- Surgical and Diagnostic Activity
- CT & MRI Activity
- Outpatient Activity
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Belgian Pharmaceutical Market at Retail Prices, 2009
- Growth Trends in Retail Pharmacy and Hospital Market, 1995-2007
- Inami spending on Retail Pharmacy Prescriptions, 2004-2007
- Reimbursable Ambulatory Prescriptions, 2002-2007
- Reimbursable Ambulatory Prescriptions by Therapeutic Category, 2005-2007
- Average Cost of Reimbursable Ambulatory Prescriptions, 2003-2007 (Euros)
- Inami Share of Spending on Reimbursable Ambulatory Prescriptions,
2003-2007 (%)
- Top 25 Active Ingredients in Reimbursable Ambulatory Prescriptions, 2008
- Top 25 Active Ingredients in Reimbursable Ambulatory Prescriptions, 2007
- Inami spending on Hospital Reimbursable Prescriptions, 2000-2007 (Euros
Millions)
- Growth Trends in Hospital Market, 2000-2007
- Market Share for Generics and Cheaper Medicines, 2004-2008 (% of DDD
Volume)
- Companies Serving the Belgian Ambulatory Generics Market, 2008
- Market Projections, 2009-2014
- Growth Trends in Pharmaceutical Spending, 2006-2009 (%)
- INAMI Drugs Expenditure 2003-2009 (Euros Millions)
- Espicom Analysis of the Belgian Pharmaceutical Market, 2009
- SWOT Analysis of the Belgian Pharmaceutical Market, 2009
- Pharmaceutical Imports by Category, 2004-2008 (US$ millions)
- Pharmaceutical Import Trends
- Leading Suppliers of Raw Materials, 2008 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2008 (US$000s)
- Leading Suppliers of Medicaments, 2008 (US$000s)
- Pharmaceutical Companies Manufacturing in Belgium
- Production of Pharmaceutical Products, 2003-2007 (Euros 000s)
- Pharmaceutical Exports by Category, 2004-2008 (US$ millions)
- Pharmaceutical Export Trends
- Leading Destinations of Raw Materials, 2008 (US$000s)
- Leading Destinations of Antisera & Vaccines, 2008 (US$000s)
- Leading Destinations of Medicaments, 2008 (US$000s)
- R&D Investment by Chemical and Life Science Industries, 2003-2007
- Cost to the Drug Industry of Government Drug Containment Measures,
1990-2007
- International Price Comparison for Frequently Prescribed Drugs, 2007-2008
- New Products Approved for Reimbursement, 2007-2008
- Innovative Drugs Approved for Reimbursement by Category, 2007-2008
- Summary of Demographic Data
- Projected Population, 2009-2014
- Healthcare Expenditure, 2008
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2006
- Hospital Bed Projections, 2009-2014
- Inpatient Hospital Stays by Region & Diagnostic Groups, Rate per 1,000
Population, 2006
- Hospital Activity in Acute Hospitals by Diagnostic Groups, 2003
- Hospitalisations, 2004
- Causes of Hospitalisation in Men by Age Group, 2004 (% of hospitalisations)
- Causes of Hospitalisation in Women by Age Group, 2004 (% of
Hospitalisations)
- Growth Trends in Selected Elective Surgical Procedures, 2002
- Myocardial Revascularisations in Belgium, 2001-2005
- CT & MRI Activity, 2000-2004
- GP Patient Contacts, 1995-2005
- Doctor Contacts by Region & Diagnostic Groups, Rate per 1,000 Population,
2006
- Doctors, 2002-2008
- Other Medical Personnel, 2002-2008
- Projected Number of Physicians, 2009-2014
List of Charts
- Pharmaceutical Market, 1997-2007, Euros Billions (manufacturers' prices)
- Pharmaceutical Market: Growth Rate, 1998-2007 (%)
- Belgian Pharmaceutical Market by Sector, Manufacturers' Prices, 2007 (%)
- Ambulatory Drug Market by Value, Retail Prices, 2007 (%)
- Ambulatory Drug Market by Volume, Retail Prices, 2007 (%)
- Reimbursable Ambulatory Prescriptions, 2000-2007 (Euros Billions)
- Radar Graph of the Belgian Pharmaceutical Market, 2009
- Pharmaceutical Imports, 2000-2008
- Percentage Change in Imports, 2000-2008 (%)
- Pharmaceutical Imports by Category, 2008 (%)
- Leading Suppliers of Pharmaceuticals, 2008
- Percentage Change in Pharmaceutical Output, 2000-2007 (%)
- Pharmaceutical Exports, 2000-2008
- Percentage Change in Exports, 2000-2008 (%)
- Pharmaceutical Exports by Category, 2008 (%)
- Leading Destinations of Pharmaceuticals, 2008
- Pharmaceutical R&D Expenditure, 1997-2007 (Euros Billions)
- Average Share of Revenues from Drugs Sold in Retail Pharmacies, 2007 (%)
- Average Share of Revenues from Reimbursable Drugs Sold in Retail
Pharmacies, 2007 (%)
- INAMI Retail Drug Expenditure according to Reimbursement Category, 2006 (%)
- Belgian Wholesale Pharmacy Market by Principal Suppliers, 2008 (%)
FRANCE
- EXECUTIVE SUMMARY SUMMARY
- PHARMACEUTICAL MARKET ANALYSIS
- Size
- Market Structure
- Retail Pharmacy Sector
- Reimbursable Drugs - Retail Pharmacy Market
- CNAM Spending on Reimbursable Drugs
- Hospital Sector
- Generics Sector
- OTC Sector
- Projections & Outlook
- Cost Containment Measures for the Health Sector During 2010
- Market Growth of 2% Forecast for 2009
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- LEEM / LEEM Recherche
- LIR
- GEMME
- Local Manufacturers
- Ipsen
- Pierre Fabre
- Sanofi-Aventis
- Sanofi Pasteur
- Servier
- Multinational Manufacturers
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- GSK
- MSD
- Pfizer
- Pharmaceutical Industry Expected to Downsize in Coming Years
- Exports
- Research & Development
- Sanofi-Aventis
- Servier
- Pierre Fabre
- Ipsen
- LEEM-Recherche
- PHARMACEUTICAL REGULATORY ANALYSIS
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic drugs
- Healthcare Products Safety Agency
- Pharmaceutical Registration
- Post-marketing surveillance
- Advertising
- Pricing & Reimbursement
- Pricing
- Pricing of reimbursable medicines in the retail pharmacy market
- Price revisions
- Pricing activity
- State-Industry Framework Agreements
- Pharmacy margins
- Reference pricing (TFR)
- Pricing of hospital medicines
- Reimbursement
- Social Security Pharmaceutical Reimbursement Spending Trends
- Intellectual Property
- Supplementary Protection Certificates
- Data Exclusivity
- PHARMACEUTICAL DISTRIBUTION
- Wholesaling
- Distributors
- Alliance Healthcare
- CERP
- OCP
- Phoenix Pharma
- Retailing
- HEALTHCARE ANALYSIS
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Maternal Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- HIV/AIDS
- Hepatitis C / Hepatitis B
- Incidence of Non-communicable Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Hearing Impairment
- Mental/ Neurological disorders
- Musculoskeletal disorders
- Renal Disease
- Respiratory Disorders
- Healthcare System
- National Health Agencies
- Regional Health Agencies
- Public Hospitals
- Hospital Restructuring
- Regional Health Organisation Plans (SROS)
- Ambulatory Services
- Health Insurance System
- Health Expenditure
- Spending on Pharmaceuticals
- Healthcare Infrastructure
- Public Hospitals
- Private Hospital
- Non-Profitmaking Hospitals
- Commercial Clinics
- Compagnie Générale de Santé (CGS)
- Capio Santé
- Médi-Partenaires
- Vitalia
- Vedici
- Regional chains
- Inpatient Analysis
- Surgical Activity
- Obstetric Activity
- Diagnostic & Therapeutic Activity in the Private Sector
- Ambulatory Activity
- Home Hospitalisation
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the French Pharmaceutical Market at Retail Prices, 2009
- Sales of Pharmaceuticals for Human Use, 2001-2007 (manufacturers' prices)
- Sales of Pharmaceuticals for Human Use, 2001-2007 (Euros Million)
- Average Per Capita Consumption of Selected Drug Categories, 2006
- Top 20 Therapeutic Classes in Retail Pharmacy Drug Market, 2007
- Top Selling Products' Share of the Retail Pharmacy Market, 2005-2007 (%)
- Top 50 Products in Retail Pharmacy Market by Value Ranking, 2007
- Growth in Pharmaceutical Consumption, Reimbursable Products, 2003-2008
- Reimbursable Pharmaceutical Growth by Principal Factor, 2000-2008 (%)
- Pharmacy Spending on Reimbursable Products by Reimbursement Status,
2007-2008
- Top Ten Contributors to Increased Spending on Reimbursable Products, 2007
- Top Five Contributors to Reduced Spending on Reimbursable Products, 2008
- Top Ten Contributors to Reduced Spending on Reimbursable Products, 2007
- CNAM Spending on Reimbursable Drugs, Ambulatory Sector, 2008
- CNAM Spending Trends on Reimbursable Drugs, by Product Category, 2005-2008
- Pharmaceutical Expenditure Growth by Product Type, 2008
- Top 50 Prescription Products Reimbursed in 2008
- Spending on Specialist Drugs Financed Separately From DRG-Based Fee
System, 2006-2008
- Top 20 Therapeutic Classes in Hospital Drug Market, 2007
- Top 50 Products in Hospital Market by Value Ranking, 2007
- Sales of Reimbursable Generics in Retail Pharmacy Market, 2002-2007
- Reimbursable Market by Patent Status, 2007
- Top 30 Best selling generics, 2007
- Generics Penetration Objectives by Volume, 2008
- Companies Serving the French Generics Market, 2006
- Market Projections, 2009-2014
- CNAM Spending on Drugs, Ambulatory Sector, January-June 2009 (Euros
Million)
- Espicom Analysis of the French Pharmaceutical Market, 2009
- SWOT Analysis of the French Pharmaceutical Market, 2009
- Pharmaceutical Imports by Category, 2003-2007 (US$ millions)
- Pharmaceutical Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Trends in Pharmaceutical Manufacturing Industry, 2000-2006
- Pharmaceutical Manufacturing Industry by Principal Sector, 2006
- Production of Medicaments and Vaccines for Human Use, 2004-2007 (Euros
Million)
- Members of LEEM Recherche, 2007
- Members of LIR, 2007
- Members of GEMME, 2007
- Pharmaceutical Exports by Category, 2003-2007 (US$ millions)
- Pharmaceutical Export Trends
- Leading Destinations of Raw Materials, 2007 (US$000s)
- Leading Destinations of Antisera & Vaccines, 2007 (US$000s)
- Leading Destinations of Medicaments, 2007 (US$000s)
- Pharmaceutical Industry R&D Expenditure, 1995-2006
- Drug Pricing Applications Submitted by Type, 2008
- Average Number of Days Taken to Process First-Time Registrations, 2008
- Taxes and Other Financial Contributions Imposed on Pharmaceutical
Companies, 2000-2007
- Distribution of the Pharmaceutical Market According to Reimbursement Rate,
2007-2008
- Social Security Drug Reimbursement, 2003-2006
- Active Pharmacies According to Legal Status, 2001
- Summary of Demographic Data
- Projected Population, 2009-2014
- Causes of Death, 2006
- Long-Term Illnesses (New Cases), 2003-2007
- Projected Growth in Patients with Cancer, Regime General, 2006-2015
- Projected Growth in Patients with Cardiovascular Disorders, Regime
General, 2006-2015
- Projected Growth in Patients with Mental/Neurological Disorders, Regime
General, 2006-2015
- Summary of Healthcare Expenditure
- Health Expenditure, 2000-2008
- Projected Health Expenditure, 2009-2014
- Spending Trends on Pharmaceuticals, Ambulatory Sector, 2003-2008
- Pharmaceutical Expenditure by Source of Funding, 2003-2008 (%)
- Summary of Hospitals & Beds
- Selected Medical Equipment Installed at French Hospitals by Sector, 2007
- Hospital Bed Projections, 2009-2014
- Hospital Activity, 2004-2007
- Hospital Activity by Specialty, 2007
- Hospital Activity in Short-Stay Units, 2003-2007
- Diagnostic and Therapeutic Procedures Performed in Public and Private
Hospitals, 2006
- Medical Personnel, 2000-2007
- Doctors by Specialty and Sector, 2003-2007
- Doctors by Sector, 2007
- Projected Number of Physicians, 2009-2014
List of Charts
- Pharmaceutical Market Growth Rates by Sector, 1997-2007
- Distribution of the French Pharmaceutical Market by Size of Market Share,
2007 (%)
- Retail Pharmacy Market by Product Status, 2007, Value %
- Retail Pharmacy Market by Product Status, 2007, Volume %
- Retail Pharmacy Market Growth Rates, 2000-2007
- Retail Pharmacy Market: Turnover by Therapeutic Area, 2007 (%)
- Retail Pharmacy Market: Volume by Therapeutic Area, 2007 (%)
- Distribution of the Reimbursable Market by Age of Presentations, 2008 (%)
- Growth in Reimbursable Drug Expenditure, Regime General, 2002-2009
- Growth in Drug Reimbursements by Category, Regime General, 2008 (Euros
Million)
- Growth in Drug Reimbursements by Prescriber, Regime General, 2008 (Euros
Million)
- Distribution of the OTC Pharmaceutical Market by Product Status, 2008 (%)
- Annual Growth Rate in Spending on Reimbursable Drugs, 2000-2009 (%)
- Radar Graph of the French Pharmaceutical Market, 2009
- Pharmaceutical Imports, 1999-2007
- Change in Pharmaceutical Imports, 1999-2007 (%)
- Pharmaceutical Imports by Category 2007 (%)
- Leading Suppliers of Pharmaceuticals, 2007 (%)
- Pharmaceutical Exports, 1999-2007
- Change in Pharmaceutical Exports, 1999-2007 (%)
- Pharmaceutical Exports by Category, 2007 (%)
- Leading Destinations of Pharmaceuticals, 2007
- R&D Employment within the French Pharmaceutical Industry, 1995-2005 (%)
- Clinical Trials Initiated, 1995-2006 (%)
GERMANY
- EXECUTIVE SUMMARY SUMMARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Retail Pharmaceutical Expenditure
- Hospital-only Drugs Market
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Association(s)
- Bundesverband der Pharmazeutischen Industrie (BPI)
- Bundesfachverband der Arnzeimittelsteller (BAH)
- Verband Forschender Arnzeimittelhersteller (VFA)
- Deutscher Generika Verband (formerly VAP)
- Research-based Manufacturers
- Bayer
- Berlin-Chemie AG
- Boehringer Ingelheim
- Fresenius Kabi AG
- Merck KGaA
- Nycomed (Altana Pharma)
- Generic Manufacturers
- Accedo Arzneimittel GmbH
- Actavis Deutschland
- betapharm
- CT-Arzneimittel
- Heumann Pharma Generics/Torrent Pharmaceuticals
- Hexal
- Hospira Deutschland GmbH
- Mylan Dura (formerly Merck Dura)
- Neuraxpharm
- ratiopharm
- Ribosepharm
- Sandoz
- Stada Arzneimittel
- Winthrop Arzneimittel
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic Drugs
- Pricing & Reimbursement
- Pricing
- Reimbursement
- GKV Negotiates Pharmaceutical Discount Contracts
- Generic Substitution Policies
- Compulsory Manufacturer Rebates
- AVWG, 2006
- Intellectual Property
- Supplementary Protection Certificates
- Data Exclusivity
- Pharmaceutical Distribution
- Wholesaling
- Anzag
- Celesio
- Noweda eG
- Phoenix AG
- Sanacorp Pharmahandel AG
- Retailing
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- HIV/AIDS
- Healthcare System
- Federal Ministries
- Länder Institutions
- Healthcare System Reform 2007
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
List of Tables
- Summary of Key Data Projections, 2009-14
- Summary of the German Pharmaceutical Market, 2009
- Total Retail Pharmaceutical Expenditure, 2001-07 (Euro billions)
- GKV Prescription Drug Expenditure, 1996-2007
- GKV Drug Spending by Therapeutic Category, 2005-07 (Euro millions)
- GKV Drug Spending by Therapeutic Category, 2005-07 (Packages prescribed,
millions)
- Top 30 selling Drug Brands, 2007
- GKV Pharmaceutical Expenditure by Land, 2006-07 (million euros)
- Sales of Hospital-only Pharmaceuticals, 2002-06 (Million Euros)
- Prescriptions of Hospital-only Pharmaceuticals, 2002-06 (000s)
- Average Price of Hospital-only Pharmaceuticals, 2002-06 (Euros)
- Generic market share by volume and value, 2001-07 (%)
- Generic Spending, 2001-2006 (million euros)
- Generics in the ‘Generic Capable’ Market, 2001-2007 (%)
- Potential Generic Savings for 20 Leading Products, 2007
- OTC Market by Category, 2001-07 (million euros)
- Market Projections, 2009-2014
- Market Projections by Category, 2009-2014 (million euros)
- Market Projections by Category, 2009-2014 (US$ millions)
- Per Capita Market Projections by Category, 2009-2014 (US$)
- SWOT Analysis of the German Pharmaceutical Market
- Espicom Analysis of Germany's Health Sector
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Total Pharma Production, 1992-2007 (Euro billions)
- Eurostat Production Data, 2003-07 (Euro millions)
- Exports of Pharmaceuticals, 2003-07 (US$000s)
- Export Trends
- Leading Destinations, 2007 (US$000s)
- Public and Hospital Pharmacies, 2002-06
- Pharmacies by Land, 2006
- Pharmacists by Land, 2002-06 (Rate per 100,000 population)
- Summary of Demographic Data
- Projected Population, 2009-14
- Causes of Death, 2006-07
- Health Expenditure by Source, 2002-06 (million euros)
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds
- Hospital Bed Projections, 2009-14
- Total Doctors & Dentists, 2002-06
- Projected Total Number of Physicians, 2009-14
- Physicans by Specialty, 2005-07
List of Charts
- Pharmaceutical Market by Type, 2007 (%)
- Radar Graph of the German Healthcare System
- VFA Member Company R&D Expenditure, 2000-07 (million euros)
IRELAND
- EXECUTIVE SUMMARY SUMMARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Generics Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Association(s)
- Irish Pharmaceutical Healthcare Association (IPHA)
- Association of Pharmaceutical Manufacturers of Ireland (APMI)
- Pharmaceutical Manufacturers
- Actavis
- Abbott Laboratories
- Allergan
- Astellas
- Bristol-Myers Squibb
- Eli Lilly
- Johnson & Johnson
- Leo Pharma
- Merck Sharp & Dohme
- Novartis
- Pfizer
- Pinewood Healthcare
- Recordati
- Roche
- Servier
- Schering Plough
- Stada Arzneimittel
- Takeda
- Wyeth
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Advertising
- Pricing & Reimbursement
- Price cuts for patent-expired brands
- Wholesale price margins
- Pharmacy mark-ups
- Intellectual Property
- Supplementary Protection Certificates
- Data exclusivity
- Pharmaceutical Distribution
- Wholesaling
- Cahill May Roberts (Celesio)
- United Drug Wholesale
- Uniphar Group
- Retailing
- Unicare Pharmacies (Celesio)
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Incidence of Cancer
- HIV/AIDS
- Healthcare System
- Health Expenditure
- Health Estimates for 2009
- Supplementary budget doubles health contributions, April 2009
- Projected health expenditure
- Healthcare Infrastructure
- Private sector
- National Paediatric Hospital
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-14
- Summary of the Irish Pharmaceutical Market, 2009
- GMS Expenditure by Leading Therapy Areas, 2006
- Market Projections, 2009-14
- SWOT Analysis of the Irish Pharmaceutical Market, 2008
- Espicom Analysis of Ireland's Health Sector
- Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- IPHA Members, 2008
- Exports of Pharmaceuticals, 2003-2007 (US$000s)
- Export Trends
- Leading Destinations, 2007 (US$000s)
- Authorities
- IMB Activity, 2004-07
- Community Pharmacies, 2006-08
- Summary of Demographic Data
- Projected Population, 2009-14
- Healthcare Expenditure, 2008
- HSE Income and Expenditure, 2006-07 (euros 000s)
- Total HSE Funding, 2006 -2009
- Projected Health Expenditure, 2009-14
- Hospitals & Beds
- Hospital Bed Projections, 2009-14
- Planned/Underway Infrastructure Projects, 2009-2013 (000 euros)
- Projected Number of Physicians, 2009-14
ITALY
- PHARMACEUTICAL MARKET ANALYSIS
- Size
- Market Structure
- Retail Pharmacy Sales
- SSN Pharmacy Sales
- Hospital Sales
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- ANIFA
- ASCHIMFARMA
- ASSOGENERICI
- CPA
- Farmindustria
- Local Manufacturers
- Angelini
- Chiesi Farmaceutici
- Menarini Group
- Recordati Industria Chimica e Farmaceutica
- Rottapharm
- Sigma-Tau
- Zambon
- Exports
- PHARMACEUTICAL REGULATORY ANALYSIS
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic Drugs
- Italian Drugs Agency
- Pharmaceutical Registration
- Advertising
- Pricing & Reimbursement
- Intellectual Property
- PHARMACEUTICAL DISTRIBUTION
- Wholesaling
- Alliance Healthcare
- Comifar
- Farvima
- Farmintesa
- Unico
- Retailing
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- HIV/AIDS
- Incidence of Non-communicable Diseases
- Cancer
- Healthcare System
- National Level
- Regional Level
- Local Level
- Private Health Insurance
- Health System Reforms
- Health Expenditure
- Healthcare Infrastructure
- Inpatient Analysis
- Ambulatory Care
- Community Care
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Italian Pharmaceutical Market, 2009
- Total Pharmaceutical Sales by Drug Class, 2006-2008
- Total Pharmaceutical Sales by Therapeutic Area, 2008 (Million Euros)
- Total Pharmaceutical Sales by Therapeutic Area, 2008 (%)
- Total Pharmaceutical Sales by Region, 2008 (Million Euros)
- Total Pharmaceutical Sales by Region, 2008 (%)
- Pharmacy Sales by Sector, 1997-2008 (Million Euros)
- Pharmacy Sales by Drug Class, 2003-2008 (Million Euros)
- Pharmacy Sales by Drug Class, 2003-2008 (%)
- Change in Pharmacy Sales by Drug Class, 2003-2008 (%)
- Pharmacy Sales by Drug Class, 2002-2008 (Million Units)
- Pharmacy Sales by Drug Class, 2002-2008 (%)
- Change in Pharmacy Sales by Drug Class, 2002-2008 (%)
- Per Capita Pharmaceutical Spending by Region, 2008 (Euros)
- SSN Pharmacy Sales by Type, 2003-2008 (Million Euros)
- Change in SSN Pharmacy Sales by Type, 2004-2008 (%)
- Per Capita Trends in SSN Pharmacy Sales 2003-2008
- SSN Pharmacy Sales by Therapeutic Area, 2008
- Top 30 Active Ingredients, SSN Pharmacy Sales, 2008
- SSN Pharmacy Sales by Type & Region, 2008
- Per Capita SSN Pharmacy Spending by Region, 2008 (Euros)
- Hospital Sales by Therapeutic Area, 2006 -2008
- Hospital Sales by Region, 2006-2008
- Generic Sales, 2003-2008 (Manufacturers' Prices)
- Generic Penetration by Drug Class, 2005-2008 (%)
- SSN Net Sales by Patent Status, 2004-2008(%)
- Per Capita Net SSN Expenditure on Off-Patent Products by Region, 2004-2008
(Euros)
- SSN Expenditure on Top Five Off-Patent Products, 2008
- Projected Generic Sales, 2009-2011 (Manufacturers' Prices)
- Value of Leading Active Ingredients with Recently Expired Patents
- Self-medication Sales, 2003-2008
- Self-medication Sales by Drug Class, 2006-2008
- Self-medication Sales by Therapeutic Area, 2006-2008 (Million Euros)
- Self-medication Sales by Region, 2006-2008
- Market Projections, 2009-2014
- Latest Trends in SSN Pharmacy Sales by Therapeutic Category, Jan-Sep 2008
- Espicom Analysis of the Italian Pharmaceutical Market, 2009
- SWOT Analysis of the Italian Pharmaceutical Market, 2009
- Pharmaceutical Imports by Category, 2004-2008 (US$ millions)
- Pharmaceutical Import Trends
- Leading Suppliers of Raw Materials, 2008 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2008 (US$000s)
- Leading Suppliers of Medicaments, 2008 (US$000s)
- Pharmaceutical Industry Key Indicators, 2001-2007
- Pharmaceutical Workforce by Leading Region, 2007
- Pharmaceutical Industry by Size of Company, 2005
- Pharmaceutical Production at Manufacturers' Prices, 2005-2007 (Million
Euros)
- Members of ANIFA, 2007
- Pharmaceutical Exports by Category, 2004-2008 (US$ millions)
- Pharmaceutical Export Trends
- Leading Destinations of Raw Materials, 2008 (US$000s)
- Leading Destinations of Antisera & Vaccines, 2008 (US$000s)
- Leading Destinations of Medicaments, 2008 (US$000s)
- Pharmaceutical R&D Expenditure, 2000-2007
- Pharmaceutical R&D Workforce, 2000-2007
- Pharmaceutical R&D Expenditure by Leading Region, 2006
- Pharmaceutical R&D Expenditure by Type, 2006 (Million Euros)
- Clinical Studies by Phase, 2000-2007 (%)
- Clinical Studies by Leading Therapeutic Area, Cumulative 2000-Mid 2007
- AIFA's Structure, 2006
- Total Number of Pharmaceutical Products & Presentations, 2001-2007
- Number of SSN Pharmaceutical Products & Presentations, 2002-2008
- Wholesalers by Region, 2000-2005
- SSN Pharmacy Discounts
- Pharmacies by Region & Sector, 2008
- Summary of Demographic Data
- Projected Population, 2009-2014
- Deaths by Cause & Sex, 2006
- Oncology Screening Programme, 2006
- Healthcare Expenditure, 2008
- Health Expenditure, 2001-2007 (Euros billion)
- Public Health Expenditure by Region, 2007
- Projected Health Expenditure, 2009-2014
- Hospitals & Beds, 2006
- Hospital Bed Projections, 2009-2014
- Hospital Activity, 2001-2005
- Hospital Activity by Sector, 2005
- Ambulatories & Laboratories by Sector, 2002-2006
- Ambulatories & Laboratories by Macro-Region, 2005
- Registered Doctors and Dentists, 2000-2006
- Projected Number of Physicians, 2009-2014
- Registered Doctors by Specialty, 2005
List of Charts
- Pharmaceutical Market by Sector, 2008 (%)
- Total Pharmaceutical Sales by Drug Class, 2008 (%)
- Pharmacy Sales by Sector, 1998-2008, Billion Euros
- Percentage Change in Pharmacy Sales by Value, 2002-2008 (%)
- Percentage Change in Pharmacy Sales by Volume, 2002-2008 (%)
- Pharmaceutical Market by Patent Status, 2008 (% of Sales by Value)
- Radar Graph of the Italian Pharmaceutical Market, 2009
- Pharmaceutical Imports, 2000-2008
- Percentage Change in Imports, 2000-2008 (%)
- Pharmaceutical Imports by Category, 2008 (%)
- Leading Suppliers of Pharmaceuticals, 2008 (%)
- Pharmaceutical Exports, 2000-2008
- Percentage Change in Exports, 2000-2008 (%)
- Pharmaceutical Exports by Category, 2008 (%)
- Leading Destinations of Pharmaceuticals, 2008 (%)
NETHERLANDS
- EXECUTIVE SUMMARY SUMMARY
- PHARMACEUTICAL MARKET ANALYSIS
- Size
- Market Structure
- Reimbursable Drugs - Pharmacy Sector
- Community Pharmacies
- Chronic Ailment Repeat Prescriptions Increase
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- Local Manufacturers
- Organon
- DSM BV
- Multipharma B.V
- Pharmachemie B.V.
- Exports
- Research & Development
- PHARMACEUTICAL REGULATORY ANALYSIS
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic Drugs
- Pharmaceutical Registration
- Advertising
- Pricing & Reimbursement
- Pricing
- Medicines Covenant (2004-2007)
- Reimbursement
- Intellectual Property
- PHARMACEUTICAL DISTRIBUTION
- Wholesaling
- Brocacef Holding
- Interpharm Group BV (Alliance Healthcare)
- Mediq (OPG)
- Retailing
- HEALTHCARE ANALYSIS
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- HIV/AIDS
- Incidence of Non-communicable Diseases
- Cancer
- Diabetes
- Healthcare System
- Dutch Healthcare Authority (NZa)
- Health Care Inspectorate (IGZ)
- Institutional Care
- Hospital Diagnosis Treatment Combinations (DBCs)
- Ambulatory Care
- Health Insurance
- Health Insurance Act
- The Exceptional Medical Expenses Act (EMEA)
- Supplementary Health Insurance
- HEALTH EXPENDITURE
- Healthcare Infrastructure
- Inpatient Analysis
- Ambulatory Activity
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Dutch Pharmaceutical Market, 2009
- Turnover by Sector, Manufacturers' Prices, 2003-2008 (Million Euros)
- Market Value by Sector and Product Type, 2008
- Market Volume by Sector and Product Type, 2008
- Pharmacy Sales of Reimbursable Drugs, 2004-2008
- Pharmacy Sales of Reimbursable Drugs by Category, 2004-2008 (000s Euros)
- Pharmacy Sales of Reimbursable Drugs by Category, 2004-2008 (DDD 000s)
- Pharmacy Sales of Reimbursable Drugs by Category, 2004-2008 (Cost per DDD)
- Pharmacy Sales of Reimbursable Drugs by Category, 2004-2008 (Prescriptions
000s)
- Trends in Pharmacy Sales of Reimbursable Drugs, 2004-2008
- Top 10 Drugs by Expenditure, 2008 (Million Euros)
- Top 10 Prescribed Drugs by Prescription, 2008
- Market Share of New Drugs in Reimbursable Market, 2000-2007
- Market Share of New Drugs in Reimbursable Market, 2000-2007
- Community Pharmacy Drug Sales, 2003-2007
- Generic Share of Pharmacy Market by Volume, 2003-2007 (Million
Prescriptions)
- Generic Share of Pharmacy Market by Value, 2003-2007 (Million Euros)
- Generic Share of Hospital Market, 2007-2008
- Top 10 Generic Drugs by Prescription, 2007
- OTC Market by Therapeutic Area, 2004-2008 (Million Euros)
- OTC Market by Point of Sale, 2008
- OTC Market by Therapeutic Area & Point of Sale, 2008 (Million Euros)
- Market Projections, 2009-2014
- Espicom Analysis of the Dutch Pharmaceutical Market, 2009
- SWOT Analysis of the Dutch Pharmaceutical Market, 2009
- Pharmaceutical Imports by Category, 2004-2008 (US$ Millions)
- Pharmaceutical Import Trends
- Leading Suppliers of Pharmaceuticals, 2008 (US$000s)
- Leading Suppliers of Raw Materials, 2008 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2008 (US$000s)
- Leading Suppliers of Medicaments, 2008 (US$000s)
- Pharmaceutical Industry Indicators, 1995-2006
- Pharmaceuticals Exports by Category, 2004-2008 (US$ millions)
- Pharmaceutical Export Trends
- Leading Destinations of Pharmaceuticals, 2008 (US$000s)
- Leading Destinations of Raw Materials, 2008 (US$000s)
- Leading Destinations of Antisera & Vaccines, 2008 (US$000s)
- Leading Destinations of Medicaments, 2008 (US$000s)
- Research & Development Expenditure of Domestic Companies, 1995-2003
(Million Euros)
- Number of Authorised Medicinal Products, 2004-2008
- Medicinal Products Recorded in the Register, 2004-2008
- Community Pharmacies, 2003-2007
- Summary of Demographic Data
- Projected Population, 2009-2014
- Causes of Death, 2007
- Healthcare Expenditure
- Projected Health Expenditure, 2008-2013
- Hospitals & Beds
- Hospital Bed Projections, 2009-2014
- Hospital Activity, 2000-2007
- Hospital Admissions by Main Diagnosis, 2002-2007
- Hospital Admissions by Type & Main Diagnosis, 2007
- Patient Days & Average Stay by Main Diagnosis, 2007
- Ambulatory Consultations, 2003-2008
- Medical Personnel, 2003-2007
- Projected Number of Physicians, 2009-2014
List of Charts
- Dutch Pharmaceutical Market by Sector, 2008 (%)
- Drug Consumption by Age Group & Gender, 2007 (prescriptions per person)
- Drug Expenditure by Age Group, & Gender 2007 (Euros)
- Impact of Cost Containment Measures on Pharmaceutical Spending, 2000-2012
(Million Euros)
- Radar Graph of the Dutch Pharma Market, 2009
- Pharmaceutical Imports, 2000-2008
- Change in Pharmaceutical Imports, 2001-2008 (%)
- Pharmaceutical Exports, 2000-2008
- Change in Pharmaceutical Exports, 2001-2008 (%)
PORTUGAL
- EXECUTIVE SUMMARY SUMMARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Pharmacy Sector
- Generics Sector
- OTC Sector
- Hospital Sector
- Projections & Outlook
- Imports
- Domestic Production
- Bial
- Bluepharma
- Hikma Farmaceutica Portugal
- Hovione
- Jaba
- Medinfar
- Labotorios Vitoria
- Pharmout
- Pharmaceutical Production, 2007
- Exports
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Drug Approvals
- Marketing Authorisations
- Post-Market Surveillance
- Labelling & Packaging
- Advertising
- Personal Selling
- Patent Protection & Intellectual Property Rights
- Pricing & Reimbursement
- EU Directive on the Transparency of Pricing & Reimbursement
- Pharmaceutical Distribution
- GROQUIFAR
- New Pharmacy Regulation
- Human Pharmaceuticals Regulation, 2006
- Trade Fairs
- Trade Associations
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of death
- Incidence of Communicable Disease
- Incidence of Non-communicable disease
- HIV/AIDS
- Obesity Platform Launched
- Healthcare System
- Ministry of Health
- National Health Service
- Regional Health Administrations
- Private Health Insurance
- Opthalmogy Intervention Wait Time Programme Launched
- Portugal Health Service Increases Online Services
- Public Hospital Privatisations
- PPP Privatisation, 2007/ 2008
- Ministry of Health Hospital Debt
- Health Expenditure
- Health Expenditure Projections
- Healthcare Infrastructure
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary Key Data Projections, 2009-2014
- Summary of the Portugues Pharmaceutical Market, 2009
- Pharmaceutical Sales by Sector, 2003-2008 (Million Euros)
- Pharmaceutical Sales by Sector, 2003-2007 (%)
- Change in Pharmaceutical Sales by Sector, 2003-2007 (%)
- Pharmacy Sales by Value & Volume, 2003-2008
- SNS Pharmacy Sales, 2002-2008
- SNS Pharmacy Sales by Month, 2007- 2008
- SNS Pharmacy Sales by Prescription Origin, 2005
- SNS Pharmacy Sales by Therapeutic Area, 2005
- SNS Pharmacy Sales by Leading Active Ingredient by Value, 2005
- SNS Pharmacy Sales by Leading Active Ingredient by Volume, 2005
- SNS Pharmacy Sales by Leading Medicine by Value, 2005
- Generic Pharmacy Sales by Value & Volume, 2003- 2008
- Generic Pharmacy Sales, 2003-2008 (Million Euros/US$)
- Generic Pharmacy Sales by Month, 2003-2008 (Million Euros)
- Generic Pharmacy Sales by Month, 2003-2008 (000 Units)
- Leading Generic Producers in the Pharmacy Sector, 2005 (%)
- OTC Sales, 2007-September 2008 (At Retail Prices, in Million Euros/Units)
- OTC Sales Outside Pharmacies, 2005-September 2008
- Hospital Sales, 2007
- Hospital Sales by Leading Hospitals, 2007
- Hospital Sales by Therapeutic Area, 2007
- Hospital Sales by Provision Area, 2007
- Market Projections, 2009-2014
- Espicom Analysis of the Portuguese Pharmaceutical Market, 2009
- Imports of Pharmaceuticals by Category, 2003-07 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Raw Material & Pharmaceutical Production 1996-2007 (Million Euro)
- Turnover by the 15 Leading Portuguese Producers, 2001-2005 (Million Euros)
- Production by the 15 Leading Portuguese Producers, 2001-2005 (Million
Units)
- Exports of Pharmaceuticals, 2003-07 (US$000s)
- Export Trends
- Leading Destinations, 2007 (US$000s)
- Projected Exports by the 15 Leading Portuguese Producers, 1999-2007
- R&D by the 15 Leading Portuguese Producers, 2001-2005
- Branded Medicines by Type, 2000-2006
- Presentations by Type, 2000-2006
- Marketing Authorisation Applications, 2001-2007
- Granted Marketing Authorisations, 2001-2007
- Non-Approved MA, 2001-2007
- MA Renewals, 2001-2006
- Completed Marketing Authorisation Procedures, 2001-2006
- ADR Notifications by National Pharmacovigilance System (NPS), 1995-2006
- ADR Notifications by Reporter, 2006
- Presentations by Price Range, 2006
- Applied, Granted & Non-Approved Reimbursements, 2000-2005
- Reimbursed Branded Medicines, 2000-2005
- Reimbursed Presentations, 2000-2005
- Branded Medicines by Reimbursement Level, 2001-2005
- Presentations by Reimbursement Level, 2001-2005
- Presentations by Reimbursement Level & Therapeutic Group, 2005
- Pharmacies, Pharmacy Extensions, Medicine Wholesalers & Drug Stores,
1990-2006
- Pharmacies & Pharmacy Extensions by Area, 2005
- Pharmaceutical Members of GROQUIFAR, 2007
- INFARMED's Listed National Manufacturers, 2007
- Members of APIFARMA, 2006
- Members of APOGEN, 2007
- Summary Demographic Data
- Projected Population, 2009-2014
- Health Regions
- ADSE Membership, 2002-2007
- Healthcare Expenditure, 2005
- Projected Health Expenditure, 2009-14
- Hospitals and Beds, 2006
- Hospital Bed Projections, 2009-2014
- Admissions, Patient Days and ALOS, 1990-2006
- Hospital Consultations by Specialty & Region, 2006
- Specialist & Non-Specialist Physicians, 1990-2007
- Projected Number of Physicians, 2009-14 (000s)
- Methodology & Sources
List of Figures
- SNS Market Growth, 2003-2006 (%)
- Pharmacy Sales by Value, 2003- 2008 (Million Euros)
- SNS Pharmacy Sales, 2002-2008
- SNS Pharmacy Sales by Leading Medicine by Retail Price & Volume 2005
(Million Euros/Units)
- Generics as % of the Pharmacy Sector, 2001-2008, by Value & Volume
- Hospital Sales by Leading Hospital, 2007
- Hospital Sales by Therapeutic Area, 2007
- Radar Graph of the Portuguese Pharmaceutical Market, 2009
- R&D by the 15 Leading Portuguese Producers, 2001-2005 (Millions Euros)
- Medicines Retail Price Structure, 2005 (%)
SPAIN
- EXECUTIVE SUMMARY SUMMARY
- Introduction
- Pharmaceutical Market Analysis
- Pharmaceutical Regulatory Analysis
- Healthcare Analysis
- Geographic Analysis
- Political Analysis
- Economic Analysis
- Pharmaceutical Market Analysis
- Current Size
- Market Structure
- Pharmacy Sales
- SNS Sector
- Generics Sector
- OTC Sector
- Projections & Outlook
- Imports
- Domestic Manufacturing
- Domestic Production
- Trade Associations
- AESEG
- ANEFP
- ASEBIO
- BIOCAT
- BIOMADRID
- FARMAINDUSTRIA
- Trade Fairs
- BIOSPAIN
- FARMAMAQ
- FISALUD
- INFARMA
- Local Manufacturers
- Almirall
- Cantabria Farmaceutica
- Esteve
- FAES
- Ferrer Internacional
- Grifols
- L´cer
- ROVI
- Salvat
- Uriach
- Zeltia
- Exports
- Research & Development
- Profarma
- EU - Innovate Medicines - Scheme
- Pharmaceutical Regulatory Analysis
- Registration
- Promotion
- Pricing & Reimbursement
- Reference Pricing
- Dual Pricing
- Co-Payment
- Intellectual Property
- Pharmaceutical Distribution Analysis
- Wholesaling
- Distributors
- ARAGOFAR
- CECOFAR
- Cofares
- Federació Farmacéutica
- HEFAME
- SAFA
- Retailing
- Composition of Pharmacy Retail Prices
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- Healthcare System
- Health Cohesion & Quality Law
- Health Expenditure
- Public Health Expenditure
- Private Health Insurance
- Private Health Insurers
- Adeslas
- Asisa
- DVK Seguros
- Mapfre Caja Salud
- Sanitas
- Healthcare Infrastructure
- Hospital Infrastructure
- Private Hospital Providers
- Private Management of Public Hospitals
- Ambulatory Infrastructure
- Healthcare Services
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- Trade Associations
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the Spanish Pharmaceutical Market, 2009
- Pharmaceutical Market by Sector at Manufacturers' Prices, 2000-2008
- Pharmacy Sales at Retail Prices, 1995-2008
- Pharmacy Sales at Manufacturers' Prices, 1995-2008
- Pharmacy Sales at Manufacturers' Prices by Sector, 2000-2008 (Million
Euros)
- Pharmacy Sales by Sector 2000-2008 (Million Units)
- Pharmacy Sales at Manufacturers Prices by Therapeutic Group, 2008 (Million
Euros)
- Pharmacy Sales at Manufacturers' Prices by Leading Company, 2008 (Million
Euros)
- Pharmacy Sales by Therapeutic Group, 2008 (Million Units)
- Gross SNS Pharmacy Sales at Retail Prices, 1995-2008 (Million Euros)
- SNS Pharmacy Prescriptions, 1995-2008 (Million)
- Net SNS Pharmacy Sales at Retail Prices by Month, 2003-2009 (Million Euros)
- Net SNS Pharmacy Sales at Retail Prices by Region, 2006-2008 (Million
Euros)
- SNS Pharmacy Prescriptions by Month, 2003-2009 (Million)
- SNS Pharmacy Prescriptions by Region, 2006-2008 (Million)
- Net SNS Pharmacy Prescription Cost by Month, 2003-2009 (Euros)
- Net SNS Pharmacy Prescription Cost by Region, 2006-2008 (Euros)
- SNS Hospital Debt at Retail Prices by Region, 2006-2007 (Million Euros)
- Generic Pharmacy Sales at Manufacturers' Prices, 2002-2008
- Generic Pharmacy Sales at Manufacturers' Prices by Leading Company, 2008
- Cumulative Savings by Using Generics by Region, 2007 (Million Euros)
- OTC Sales at Manufacturers' Prices, 2000-2008
- Market Projections, 2009-2014
- Espicom Analysis of the Spanish Pharmaceutical Market, 2009
- Pharmaceutical Imports by Category, 2003-2007 (US$000s)
- Pharmaceutical Import Trends by Category, 2006-2007 (US$000s)
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Pharmaceutical Production, 1995-2005
- Leading Pharmaceutical Companies, 2006
- Members of AESEG, 2008
- Members of ANEFP, 2008
- Members of ASEBIO, 2008
- Members of BIOMADRID, 2008
- Members of FARMAINDUSTRIA, 2008
- Almirall's First Half Net Sales by Therapeutic Area, 2007-2008 (Million
Euros)
- Net Sales by Leading Active Ingredients, 2006-2007 (Million Euros)
- Net Sales by Therapeutic Area, 2006-2007 (Million Euros)
- Esteve's Sales, 2004-2007 (Million Euros)
- FAES' Sales, 2000-2007
- Grifols' Sales by Division, 2007
- Grifols' Sales by Country/Region, 2007
- Lacer's Sales, 2003-2008 (Million Euros)
- ROVI's Sales, 2006-2008
- Pharmaceutical Exports by Category, 2003-2007 (US$000s)
- Pharmaceutical Export Trends by Category, 2006-2007 (US$000s)
- Leading Destinations of Raw Materials, 2007 (US$000s)
- Leading Destinations of Antisera & Vaccines, 2007 (US$000s)
- Leading Destinations of Medicaments, 2007 (US$000s)
- Pharmaceutical R&D Expenditure by Type, 2007-2008 (Million Euros)
- Human Medicines Registration Requests, 2003-2006
- Human Medicines Registration Evaluations, 2003-2006
- Human Medicines Registrations by Therapeutic Group, 2005-2006
- Human Medicines Notifications of Adverse Reactions, 1984-2006
- Human Medicines Clinical Trials Authorisations, 1997-2006
- Human Medicines Clinical Trials Authorisations by Region, 2006
- POM Sector by Reference Pricing Status, 2008
- Co-Payments, 2008
- Pharmacies, 1990-2008
- Pharmacies by Region, 2008
- Pharmacy Sales at Retail Prices by Distribution Channel, 2008 (%)
- Pharmacy Sales at Retail Prices (Excluding VAT) by Distribution Channel,
1995-2008 (%)
- Projected Population, 2009-2014
- Summary of Demographic Data, 2006/2008/2009
- Projected Health Expenditure, 2009-2014
- Healthcare Expenditure, 2006
- Public Health Expenditure by Functional Classification, 2002-2007
- Private Health Insurance by Type, First Half 2009
- Private Health Insurance Market, 2002-2008
- Adelas Group's Performance Indicators, 2004-2007 (Million Euros)
- Asisa's Performance Indicators, 2006-2008 (Million Euros)
- DVK Seguros' Sales by Type, 2007-2008 (Million Euros)
- Mapfre Group's Financial Indicators, 2004-2008
- Mapfre's Written & Accepted Premium in Spain by Company, 2007-2008
(Million Euros)
- Mapfre's Written & Accepted Premium in Spain by Type, 2007-2008 (Million
Euros)
- Sanitas Group's Sales by Division, 2005-2008 (Million Euros)
- Sanitas Seguros' Performance Indicators, 2005-2008
- Hospital Bed Projections, 2009-2014
- Hospitals & Beds, 2008
- Ambulatory Facilities, 2004-2008
- Summary of Inpatient Activity, 2000-2006
- Projected Number of Doctors, 2009-2014
- Registered Medical Personnel, 2000-2007
List of Charts
- Radar Graph of the Spanish Pharmaceutical Market, 2009
- Pharmaceutical Imports, 1995-2007 (US$ Billion)
- Pharmaceutical Imports by Category, 2007 (%)
- Leading Suppliers of Pharmaceuticals, 2007 (%)
- Ferrer's Sales by Therapeutic Area, (%)
- Pharmaceutical Exports, 1995-2007 (US$ Billions)
- Pharmaceutical Exports by Category, 2007 (%)
- Leading Destinations of Pharmaceuticals, 2007 (%)
- Imports, Exports & Balance of Trade in Pharmaceuticals, 1995-2007 (US$
Billion)
- Change in Pharmaceutical R&D Expenditure, 2001-2008 (%)
SWITZERLAND
- EXECUTIVE SUMMARY SUMMARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Generics Sector
- OKP Generic Market Data, 2006
- Generic Outlook
- OTC Sector
- Projections & Outlook
- Domestic Manufacturing
- Domestic Production
- Trade Association(s)
- Research-Based Manufacturers
- Actelion
- Boehringer-Ingelheim (Schweiz) GmbH
- Cilag AG
- Dr. Grossmann AG Pharmaca
- Novartis
- Roche
- Siegfried CMS AG
- Tillotts Pharma AG
- Trichema AG
- Vifor
- Generic Manufacturers
- Acino Pharma (formerly Cimex)
- Helvepharm
- Sandoz Pharmaceuticals
- Spirig
- Streuli Pharma
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- Fast track Registration
- Registered Drugs
- Post-marketing Surveillance
- Good Manufacturing Practice (GMP) Regulations
- ADR Reports
- Pricing & Reimbursement
- Intellectual Property
- Pharmaceutical Distribution
- Wholesaling
- Galenica Holding
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases
- HIV/AIDS
- Healthcare System
- Health Expenditure
- Healthcare Infrastructure
- Healthcare Personnel
List of Tables
- Summary of Key Data Projections, 2009-14
- Summary of the Swiss Pharmaceutical Market, 2009
- Pharmaceutical Market Expenditure at Manufacturers Prices, 2002-07
(SFrmillions)
- Pharmaceutical Product Pack Consumption by Distributing Source, 2002-07
(SFrmillions)
- Average Price per Medicine Pack, 2002-07 (SFr)
- Reimbursed Market Expenditure, 2002-07 (SFrmillion)
- Generics Market (Manufacturers Prices), 2002-2007
- Generics in the OKP Market, 2006
- Generics in the OKP Market, 2006 (%)
- Pro-Generic Measures, 2001-08
- OTC Expenditure by Sales Channel, 2007
- OTC Sales by Leading Therapeutic Area, 2005-07 (euro millions)
- Pharmaceutical Market Projections, 2009-14
- SWOT Analysis of the Swiss Pharmaceutical Market
- Espicom Analysis of Switzerland's Health Sector
- Imports of Pharmaceuticals by Category, 2003-07 (US$000s)
- Import Trends
- Leading Suppliers of Raw Materials, 2007 (US$000s)
- Leading Suppliers of Medicaments, 2007 (US$000s)
- Interpharma Members, Sales, R&D and Workforce, 2007 (SFrmillions)
- VIPS members, 2008
- Exports of Pharmaceuticals, 2003-07 (US$000s)
- Export Trends
- Leading Destinations, 2007 (US$000s)
- Interpharma Members, R&D Expenditure in Switzerland, 2007 (SFrmillions)
- Registered Human Preparations by Registration List, 2004-2007
- New Registrations by Category, 1999-2007
- Registered Drugs, 2000-07
- ADR Reports by Source, 2002-07
- Swiss Generic Price Level, EU comparison, 2006 (Index)
- Pharmacies by Region and Canton, 2004-07
- Drugstores, 1985-2007
- Dispensing Doctors, 1985-2007
- Summary of Demographic Data
UNITED KINGDOM
- EXECUTIVE SUMMARY SUMMARY
- Pharmaceutical Market Analysis
- Size
- Market Structure
- Prescription Medicines Market
- England
- Wales
- Scotland
- Northern Ireland
- Generics
- OTC Sector
- Projections
- Outlook
- Imports
- Domestic Production
- Trade Associations
- The Association of British Pharmaceutical Industry (ABPI)
- The Proprietary Association of Great Britain (PAGB)
- The British Generic Manufacturers Association (BGMA)
- Multinational Manufacturers
- AstraZeneca
- Eisai
- Eli Lilly
- GlaxoSmithKline
- Novartis
- Pfizer Ltd.
- ProStrakan
- Shire Pharmaceuticals Group Plc.
- Wyeth
- Exports
- Research & Development
- Pharmaceutical Regulatory Analysis
- Pharmaceutical Regulation
- EU Drug Regulation
- Centralised Procedure
- EMEA
- Generic Drugs
- National Procedures
- Medicines & Healthcare Products Regulatory Agency (MHRA)
- Advertising
- Intellectual Property
- Supplementary Protection Certificates
- Data exclusivity
- Pricing and Reimbursement
- Pricing
- PPRS Reforms, 2009
- Patient Access Schemes
- Unbranded Generic Pricing
- Reimbursement
- Pharmaceutical Distribution
- Parallel Imports
- Healthcare Analysis
- Demographics
- Population
- Birth Rate
- Death Rate
- Infant Mortality
- Life Expectancy at Birth
- Public Health
- Causes of Death
- Incidence of Communicable Diseases/ Morbidity
- HIV/ AIDS
- Cancer Incidence
- Diabetes
- Healthcare System
- Department of Health
- Strategic Health Authorities (SHAs)
- Primary Care Trusts (PCTs)
- Acute Trusts
- NHS Foundation Trusts
- NHS Care Trusts
- Ambulance Trusts
- National Healthcare Bodies
- Care Quality Commission
- National Institute for Health and Clinical Excellence (NICE)
- NHS Schemes and Initiatives
- Payment by Results
- Patient Choice
- Independent Sector Programme
- Health Expenditure
- Healthcare Infrastructure
- Inpatient Analysis
- Private Hospitals
- Independent Healthcare Groups
- BMI Healthcare
- BUPA
- HCA International
- Netcare
- NHS Trusts
- Nuffield Health
- Partnership Health Group (PHG)
- Ramsay Healthcare Ltd (formerly Capio Healthcare UK)
- Spire Healthcare
- Ambulatory Care
- Healthcare Personnel
- DIRECTORY
- Government Organisations
- UK NHS Strategic Health Authorities
- Trade Associations
- Multinational Manufacturers
List of Tables
- Summary of Key Data Projections, 2009-2014
- Summary of the UK Pharmaceutical Market in 2009
- Pharmaceutical market by Type, 2008
- UK Written Prescriptions, 2004-2008 (millions)
- UK Prescriptions by Value, 2004-2008 (£ millions)
- UK Prescriptions & Cost by Therapeutic Area, 2008
- Prescribed Drugs in England, 2008
- Top 20 Prescribed Drugs in England by Chemical Name, 2008 (Number of
Prescriptions)
- Top 20 Prescribed Drugs in England by Chemical Name, 2008 (By Value,
£000s)
- Prescribed Drugs in Wales, 2008
- Prescribed Drugs in Scotland, 2008
- Prescribed Drugs in Northern Ireland, 2008
- Generic Prescriptions Written and Dispensed in England, 2008
- Generic Prescriptions Written and Dispensed in England, 1995-2008 (%)
- Generic Prescribing Rates, England, 2004-2008 (% by volume)
- Generic Dispensing Rates, England, 2004-2008 (% by volume)
- UK OTC Sales at Retail Prices, 2006-2008 (£ millions)
- Projected Pharmaceutical Market, 2009-2014
- SWOT Analysis of the UK Pharmaceutical Market
- Espicom Analysis of the UK Pharmaceutical Market, 2009
- Imports of Pharmaceuticals by Category, 2004-2008 (US$000s)
- Import Trends, 2004-2008 (US$000s)
- Leading Suppliers of Raw Materials, 2008 (US$000s)
- Leading Suppliers of Medicaments, 2008 (US$000s)
- UK Pharmaceutical Production, 2005-2008 (£000s)
- Exports of Pharmaceuticals, 2004-2008 (US$000s)
- Export Trends, 2007-2008 (US$000s)
- Leading Destinations, 2008 (US$000s)
- Pharmaceutical R&D expenditure in the UK, 1972-2006 (£ million)
- NICE Appraisals in Development, October 2009
- Summary of Demographic Data, 2007
- Projected Population, 2009-2014
- Total UK Health Expenditure, 1997-2004 (£ millions)
- Departmental Expenditure Limits - Resource and Capital budgets
2005/06-2007/08 (£ billions)
- Public and Private Health Expenditure, 1997-2002 (£ billions)
- Projected Health Expenditure, 2009-2014
- UK Hospital Beds, 2007/08
- Hospital Bed Projections, 2009-2014
- UK, Average length of stay, 2006/07
- UK Beds and Patient Activity by Broad Specialty, 2007/08
- Operations performed in English Hospitals, 2006/07
- Hospital Ambulatory Attendances in the UK by Broad Specialty, 2006/07
(000s)
- UK Physicians by Grade, 1999-2004
- Projected Total Number of Physicians, 2009-2014
- Consultants by Specialty in the UK, 2007
- Dentists, 2006
List of Figures
- Radar Graph of the UK Pharmaceutical Market, 2009
- Public/Private Health Expenditure, 1997-2002 (£ billions)
|
 |
